立体定向消融放疗对老年早期非小细胞肺癌安全高效
该研究回顾性分析了772例接受SABR的早期NSCLC患者,其中330例年龄≥75岁。结果显示老年与年轻患者在至进展时间、肺癌特异性生存和毒性上无差异,但5年总生存较低;老年患者无4-5级毒性。与历史手术结果相比,SABR疗效相当且并发症更少。
要点
- 老年(≥75岁)与年轻早期NSCLC患者SABR后至进展时间和肺癌特异性生存无差异。
- 老年患者SABR后无4级或5级毒性,毒性风险未增加。
- 老年患者5年总生存低于年轻患者,但SABR疗效与历史手术相当且并发症更少。
核心结论
- SABR对老年早期NSCLC的疗效与平均年龄人群相同,且不增加毒性,与历史手术结果相当但并发症更少。
研究设计与样本
- 单中心回顾性研究,纳入2004-2014年接受SABR的772例临床I-II期NSCLC患者(<75岁442例,≥75岁330例),中位随访约55个月。
主要发现
- 老年与年轻患者在至进展时间(P=.419)、肺癌特异性生存(P=.275)和毒性(P=.536)上无差异。
- 老年患者1年、3年、5年总生存率分别为86%、57.5%、39.5%;年轻患者分别为87.3%、67.6%、51.5%。
- 老年患者中无任何4级或5级毒性发生。
关键数值与推荐
- SABR方案为50 Gy分4次或70 Gy分10次。
- 老年患者(≥75岁)1年、3年、5年总生存率分别为86%、57.5%、39.5%。
临床怎么用
- 对于≥75岁早期NSCLC患者,SABR可作为有效且低毒的治疗选择。
- 临床决策时可参考SABR与历史手术结果相当但并发症更少的证据。
局限性
- 本研究为单中心回顾性分析,与手术的比较基于历史数据而非同期对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To discern the effectiveness and toxicity of stereotactic ablative radiation therapy (SABR) in the elderly population (aged ≥75 years) and to consider how SABR outcomes compare with surgical outcomes historically reported in the elderly. METHODS AND MATERIALS: A total of 772 patients with clinical early-stage I-II non-small cell lung cancer (NSCLC; stage T1-T3N0M0) underwent SABR (50 Gy in 4 fractions or 70 Gy in 10 fractions) from 2004 to 2014 at our center (n=442, aged <75 years; n=330, aged ≥75 years). The primary endpoints included overall survival (OS), time-to-progression, and grade ≥3 toxicity. The median follow-up time was approximately 55 months. RESULTS: Compared with patients aged <75 years, those aged ≥75 years had no difference in the time-to-progression (P=.419), lung cancer-specific survival (P=.275), or toxicity (P=.536). OS was the same between both age groups at 2 years of follow-up but diverged thereafter, with patients aged <75 years when treatment began having greater OS rates at 5 years. The median OS rates for patients aged ≥75 years were 86% at 1 year, 57.5% at 3 years, and 39.5% at 5 years. The median OS rates for patients aged <75 years were 87.3% at 1 year, 67.6% at 3 years, and 51.5% at 5 years. No patient aged ≥75 years experienced any grade 4 or 5 toxicity. CONCLUSIONS: The effectiveness of SABR was the same for the elderly as for the average-age population according to lung cancer-specific survival and time-to-progression. It also poses no increased toxicity. Compared with the historical outcomes with surgery in the elderly, SABR outcomes can be considered comparable for stage I-II disease but with less morbidity.
引用
- Brooks ED, Sun B, Zhao L, et al. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28258887. doi:10.1016/j.ijrobp.2016.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。